Drug application
GAVRETO (PRALSETINIB)
Drugs@FDA NDA 213721 · RIGEL PHARMS
Key facts
| Drug name | GAVRETO |
|---|---|
| Active ingredients | PRALSETINIB |
| Application type | NDA |
| Application number | 213721 |
| Company | RIGEL PHARMS |
| Dosage forms | CAPSULE, ORAL |
| Strength | 100MG |
| Marketing status | Prescription |
| Reference listed drug | Yes |
| Latest submission class | Type 1 - New Molecular Entity |
| Latest submission status date | Sep 4, 2020 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
- No FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: